StockData
Sight Sciences, Inc. logo

Sight Sciences, Inc. (SGHT) stock

SGHTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30168% above fair value
$10.49−0.10 (-0.94%)

Close on Nov 17, 2026Market cap $577.87MP/E –Yield –

Sight Sciences, Inc. grew revenue 9.3% to $83.38M over the twelve months to Jun 30, 2026. Free cash flow was -$23.33M. At the latest close the market valued the company at $577.87M.

Revenue
$83.38M
+9.3% vs. a year earlier
Operating income
-$27.88M
TTM Q2 2026
Free cash flow
-$23.33M
TTM Q2 2026
EPS, diluted
-$0.56
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$577.87M
P/E ratio
–
Price to sales
6.93
Price to book
10.93
Dividend yield
–
Free cash flow yield
-4.04%

Fundamentals

Revenue
$83.38M
Net income
-$29.76M
EPS, diluted
-$0.56
Free cash flow
-$23.33M
Book value per share
$0.97
Diluted shares
55M

Trading

Next earnings
Mar 3, 2027 (estimated, after the close)
Previous close
$10.59
Open
$10.50
Day's range
$10.32 – $10.69
Volume
271,335
Average volume (20 days)
405,763
Index membership
Russell 2000 (since Sep 2021)
52-week range
$3.38 – $11.60
RSI (14 days)
64.2
Volatility (1 year)
72.1%
Relative volume
0.64×

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodSGHTS&P 500DifferenceSGHT per yearS&P 500 per year
1 month+26.7%-4.0%+30.7 pts
3 months+27.3%-5.0%+32.3 pts
Year to date+32.3%+8.2%+24.0 pts
1 year+49.2%+11.2%+38.0 pts
3 years+366.2%+68.5%+297.7 pts+67.1%+19.0%
5 years-52.1%+67.3%−119.4 pts-13.7%+10.8%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Revenue

$83.38M+9.3% YoY

Gross profit

$73.34M+12.6% YoY

Operating income

-$27.88M

Net income

-$29.76M

EPS, diluted

-$0.56

Free cash flow

-$23.33M
Reported periodTrailing twelve months

Press releases

Releases Sight Sciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Sight Sciences

Surgical & Medical Instruments & Apparatus

Sight Sciences, Inc. is an ophthalmic medical device company that develops surgical and therapeutic technologies for eye conditions, primarily glaucoma and dry eye disease. The company operates in two segments: Interventional Glaucoma and Interventional Dry Eye. In the Interventional Glaucoma segment, it offers the OMNI Surgical System to reduce intraocular pressure in adults with primary open-angle glaucoma, and the SION Surgical Instrument to excise trabecular meshwork tissue. In the Interventional Dry Eye segment, it offers the TearCare system, which applies localized heat to clear meibomian gland obstructions. Its customers are eyecare professionals, including ophthalmic surgeons, ophthalmologists, and optometrists.

Company profile, executives and history

Sight Sciences stock: common questions

What is Sight Sciences's stock price?

SGHT closed at $10.49 on Nov 17, 2026, down 0.94% on the day. Over the past 52 weeks it traded between $3.38 and $11.60.

What is Sight Sciences's market cap?

Sight Sciences was worth $577.87M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is SGHT's P/E ratio?

Sight Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.56), so it has no meaningful P/E ratio.

How much revenue does Sight Sciences make?

Sight Sciences reported revenue of $83.38M for the twelve months to Jun 30, 2026, up 9.3% from a year earlier.

Does Sight Sciences pay a dividend?

No. Sight Sciences has not paid a cash dividend over the last twelve months.

When does Sight Sciences report earnings next?

Sight Sciences is expected to report Q4 FY2026 results on Mar 3, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has SGHT stock performed over the past year?

Including dividends, SGHT returned +49.2% over the past year, against +11.2% for the S&P 500.

How many SGHT shares are sold short?

1M shares were sold short at the latest FINRA report, 3.08% of the float, or 4.3 days of average trading volume.

Who are Sight Sciences's competitors?

Companies most similar to Sight Sciences by business, industry and size include IRIX, LNSR, LUNG, GKOS, TELA.

See a number that looks wrong?